Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An invasive malignant neoplasm that arises from the ovary and is characterized by a predominance of clear and hobnail malignant epithelial cells.
Biomarker and diagnostic research for ovarian clear cell cancer has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and biologic therapy. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
164 publications have been identified in PubMed for ovarian clear cell cancer. Research spans Basic Science / Preclinical (30%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 49 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:09 PM UTC
Research summaries | 39 | 24% |
Disease patterns and progression | 20 | 12% |
Testing and diagnosis research | 16 | 10% |
Clinical study results | 16 | 10% |
New treatment approaches | 16 | 10% |
Patient case studies | 8 | 5% |
Wei L (2026). [PMID: 42071199](https://pubmed.ncbi.nlm.nih.gov/42071199/). *BMC Cancer*. [Gene Therapy / Novel Therapeutics]
Kyriacou I (2026). [PMID: 40911515](https://pubmed.ncbi.nlm.nih.gov/40911515/). *Oncol Res Treat*. [Review / Meta-Analysis]
Dagher C (2026). [PMID: 41775562](https://pubmed.ncbi.nlm.nih.gov/41775562/). *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. [Review / Meta-Analysis]
Sachdeva M (2026). [PMID: 41883867](https://pubmed.ncbi.nlm.nih.gov/41883867/). *Therapeutic advances in medical oncology*. [Review / Meta-Analysis]
Chae YK (2026). [PMID: 41672597](https://pubmed.ncbi.nlm.nih.gov/41672597/). *J Immunother Cancer*. [Clinical Trial Publication]
Bogani G (2026). [PMID: 42119308](https://pubmed.ncbi.nlm.nih.gov/42119308/). *Gynecol Oncol*. [Review / Meta-Analysis]
Ratka Z (2026). [PMID: 42278449](https://pubmed.ncbi.nlm.nih.gov/42278449/). *Int J Mol Sci*. [Review / Meta-Analysis]
Hellberg P (2026). [PMID: 42206767](https://pubmed.ncbi.nlm.nih.gov/42206767/). *Int J Gynecol Pathol*. [Diagnostic / Biomarker]
Arora T (2026). [PMID: 33620837](https://pubmed.ncbi.nlm.nih.gov/33620837/). *Unknown Journal*. [Diagnostic / Biomarker]
Ngoi NYL (2026). [PMID: 41548565](https://pubmed.ncbi.nlm.nih.gov/41548565/). *Lancet Oncol*. [Clinical Trial Publication]
AI-curated news mentioning ovarian clear cell cancer
Updated Jul 19, 2026
A case report highlights a durable response to the combination of pembrolizumab and axitinib in a patient with platinum-resistant ovarian clear cell carcinoma. This finding may inform future treatment strategies for this challenging cancer subtype.
Research highlights the role of RBM4 as a pro-oncogenic factor in the progression of ovarian clear cell carcinoma. This discovery could inform future therapeutic strategies targeting this specific cancer type.